

Search Notes

STN
(HCAPLUS, INSPEC, JAPIO, USPATALL)
12/6/04

=> d his

(FILE 'HOME' ENTERED AT 13:17:32 ON 06 DEC 2004)

FILE 'HCAPLUS, INSPEC, JAPIO, USPATFULL, USPAT2' ENTERED AT 13:18:36 ON 06 DEC 2004

L1 1902 S (MACROMOLECULAR?) (8A) (CRYSTAL?)
L2 77308 S (SAMPLE(4A) PREPAR?)
L3 38 S (PRESCREEN?) (6A) (PROTEIN# OR CONCENTRATION(4A) PROTEIN#)
L4 5363538 S (ASSESS? OR EVALUAT? OR TEST?)
L5 39416 S (MULTIP? OR PLURAL?) (8A) (REAGENT# OR MEDIA#)
L6 295817 S (MULTIP? OR PLURAL?) (8A) (SAMPLE# OR SAMPLE(W) PLATE# OR PLATE#
L8 71397 S (AMMONIUM(W) SULFATE)
L9 132131 S (ISOPROPANOL)
L10 485516 S (INCUBAT?)

=> s l2 and l4 and l5 and l6 and l10

L11 995 L2 AND L4 AND L5 AND L6 AND L10

=> s (prescreen? or review?) (8a) (protein# or concentrat?(8a)protein#)

L12 80007 (PRESCREEN? OR REVIEW?) (8A) (PROTEIN# OR CONCENTRAT?(8A) PROTEIN#)

=> s l11 and l12

L13 66 L11 AND L12

=> d l13 1-66 abs,bib

L13 ANSWER 1 OF 66 HCAPLUS COPYRIGHT 2004 ACS on STN

AB A kit for **prescreening protein** concentration for crystallization includes a **multiplicity** of vials, a **multiplicity** of pre-selected **reagents**, and a **multiplicity** of **sample plates**. The **reagents** and a corresponding **multiplicity** of **samples** of the protein in solns. of varying concns. are placed on sample plates. The sample plates containing the reagents and samples are **incubated**. After **incubation** the sample plates are examined to determine which of the sample concns. are too low and which the sample concns. are too high. The sample concns. that are optimal for protein crystallization are selected and used.

AN 2004:141663 HCAPLUS

DN 140:177864

TI Protein crystallography prescreen kit

IN Segelke, Brent W.; Krupka, Heike N.; Rupp, Bernhard

PA The Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004033181	A1	20040219	US 2002-218764	20020814
PRAI	US 2002-218764		20020814		

L13 ANSWER 2 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, and 46508 nucleic acid molecules, which encode novel human hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 nucleic

acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 gene has been introduced or disrupted. The invention still further provides isolated 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 proteins, fusion proteins, antigenic peptides and anti-26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:274256 USPATFULL
TI Novel human hydrolase family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2004214758 A1 20041028
AI US 2002-193452 A1 20020711 (10)
RLI Continuation-in-part of Ser. No. US 2001-816664, filed on 23 Mar 2001, ABANDONED
PRAI US 2000-191973P 20000324 (60)
US 2000-199559P 20000425 (60)
US 2000-206036P 20000522 (60)
US 2000-205442P 20000519 (60)
US 2000-209949P 20000606 (60)
US 2000-214948P 20000629 (60)
US 2000-220008P 20000721 (60)
US 2000-220040P 20000721 (60)
US 2000-226774P 20000821 (60)
US 2000-235033P 20000925 (60)
US 2000-238170P 20001005 (60)
US 2001-267054P 20010207 (60)
US 2000-213688P 20000623 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 62 Drawing Page(s)
LN.CNT 68657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 66 USPATFULL on STN

AB The present invention provides compositions and methods for the detection and characterization of mutations associated with non-syndromic hearing impairment. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the Connexin 26, or gap junction beta 2, gene associated with non-syndromic hearing loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:260538 USPATFULL
TI Connexin allele detection assays
IN Mast, Andrea L., Oregon, WI, UNITED STATES
Dorn, Erin, Cross Plains, WI, UNITED STATES
Kwiatkowski, Robert J., JR., Verona, WI, UNITED STATES
Accola, Molly, Madison, WI, UNITED STATES

Wigdal, Susan S., Madison, WI, UNITED STATES
PA Third Wave Technologies, Inc., Madison, WI (U.S. corporation)
PI US 2004203035 A1 20041014
AI US 2004-754408 A1 20040109 (10)
PRAI US 2003-438963P 20030109 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA,
94105
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:171926 USPATFULL
TI Novel human enzyme family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksman, Maria Alexandria, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, 02139 (U.S. corporation)
PI US 2004132087 A1 20040708
AI US 2004-776871 A1 20040211 (10)
RLI Continuation of Ser. No. US 2002-175696, filed on 20 Jun 2002, PENDING
Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002,
ABANDONED Continuation-in-part of Ser. No. US 2001-823901, filed on 30
Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US10720,
filed on 2 Apr 2001, PENDING Continuation-in-part of Ser. No. US
2001-862658, filed on 21 May 2001, ABANDONED Continuation-in-part of
Ser. No. WO 2001-US16380, filed on 21 May 2001, PENDING
Continuation-in-part of Ser. No. US 2001-882837, filed on 15 Jun 2001,
ABANDONED Continuation-in-part of Ser. No. WO 2001-US19319, filed on 15
Jun 2001, PENDING
PRAI US 2001-266140P 20010202 (60)
US 2000-193920P 20000331 (60)
US 2000-205675P 20000519 (60)
US 2000-211727P 20000615 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA,
02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)

LN.CNT 21375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 66 USPATFULL on STN

AB The present invention provides systems, methods, and screens to measure receptor internalization in a single step with appropriate automation and throughput. This approach involves luminescent labeling of the receptor of interest and the automated measurement of receptor internalization to a perinuclear location.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:167984 USPATFULL

TI System for cell-based screening

IN Rubin, Richard A., Pittsburgh, PA, United States
Giuliano, Kenneth A., Pittsburgh, PA, United States
Gough, Albert H., Glenshaw, PA, United States
Dunlay, R. Terry, New Kensington, PA, United States

PA Cellomics, Inc., Pittsburgh, PA, United States (U.S. corporation)

PI US 6759206 B1 20040706

AI US 1999-352171 19990712 (9)

RLI Continuation-in-part of Ser. No. US 1998-31271, filed on 27 Feb 1998, now abandoned Continuation-in-part of Ser. No. US 1997-810983, filed on 27 Feb 1997, now patented, Pat. No. US 5989835

PRAI US 1998-92671P 19980713 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Le, Long V.; Assistant Examiner: Cook, Lisa V

LREP McDonnell Boehnen Hulbert & Berghoff LLP

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 39 Drawing Figure(s); 30 Drawing Page(s)

LN.CNT 3383

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 66 USPATFULL on STN

AB The present invention provides systems, methods, and screens to measure receptor internalization in a single step with appropriate automation and throughput. This approach involves luminescent labeling of the receptor of interest and the automated measurement of receptor internalization to a perinuclear location.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:133376 USPATFULL

TI System for cell-based screening

IN Rubin, Richard A., Pittsburgh, PA, UNITED STATES
Giuliano, Kenneth A., Pittsburgh, PA, UNITED STATES
Gough, Albert H., Glenshaw, PA, UNITED STATES
Dunlay, R. Terry, New Kensington, PA, UNITED STATES
Conway, Bruce Ray, Doylestown, PA, UNITED STATES

PA Cellomics, Inc. (U.S. corporation)

PI US 2004101912 A1 20040527

AI US 2003-685737 A1 20031015 (10)

RLI Continuation of Ser. No. US 1999-352171, filed on 12 Jul 1999, PENDING
Continuation-in-part of Ser. No. US 1997-810983, filed on 27 Feb 1997, GRANTED, Pat. No. US 5989835

PRAI US 1998-92671P 19980713 (60)

DT Utility

FS APPLICATION

LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN 30 Drawing Page(s)

LN.CNT 3425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 66 USPATFULL on STN

AB Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:116712 USPATFULL

TI Nucleic acid encoding 15571, a GPCR-like molecule of the secretin-like family

IN Hodge, Martin R., Arlington, MA, United States

Lloyd, Clare, London, UNITED KINGDOM

Weich, Nadine S., Brookline, MA, United States

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 6733990 B1 20040511

AI US 2000-631603 20000803 (9)

RLI Continuation-in-part of Ser. No. US 2000-515781, filed on 29 Feb 2000, now abandoned

PRAI US 1999-146916P 19990803 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Mertz, Prema

LREP Millennium Pharmaceuticals, Inc.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 28 Drawing Figure(s); 28 Drawing Page(s)

LN.CNT 4954

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:109094 USPATFULL

TI 18431 and 32374, novel human protein kinase family members and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Silos-Santiago, Immaculada, Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004083496 A1 20040429

AI US 2003-678786 A1 20031003 (10)

RLI Continuation of Ser. No. US 2001-916790, filed on 27 Jul 2001, ABANDONED

PRAI US 2000-221543P 20000728 (60)

DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 6026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 66 USPATFULL on STN

AB The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is microplate having cells in a micropatterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:103678 USPATFULL
TI System for cell-based screening
IN Dunlay, R. Terry, New Kensington, PA, United States
Taylor, D. Lansing, Pittsburgh, PA, United States
Gough, Albert H., Glenshaw, PA, United States
Giuliano, Kenneth A., Pittsburgh, PA, United States
PA Cellomics, Inc., Pittsburgh, PA, United States (U.S. corporation)
PI US 6727071 B1 20040427
WO 9838490 19980903
AI US 1999-380259 19991208 (9)
WO 1998-US3701 19980227
RLI Continuation-in-part of Ser. No. US 1997-810983, filed on 27 Feb 1997, now patented, Pat. No. US 5989835
PRAI US 1997-69329P 19971211 (60)
US 1997-69249P 19971211 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Gabel, Gailene R.
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 3071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 66 USPATFULL on STN

AB The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to

determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropatterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:82711 USPATFULL
TI System for cell-based screening
IN Dunlay, R. Terry, New Kensington, PA, UNITED STATES
Taylor, D. Lansing, Pittsburgh, PA, UNITED STATES
Gough, Albert H., Glenshaw, PA, UNITED STATES
Giuliano, Kenneth A., Pittsburgh, PA, UNITED STATES
PA Cellomics, Inc. (U.S. corporation)
PI US 2004063162 A1 20040401
AI US 2003-686161 A1 20031015 (10)
RLI Continuation of Ser. No. US 2000-724376, filed on 27 Nov 2000, GRANTED,
Pat. No. US 6671624 Division of Ser. No. US 1998-31271, filed on 27 Feb
1998, ABANDONED Continuation-in-part of Ser. No. US 1997-810983, filed
on 27 Feb 1997, GRANTED, Pat. No. US 5989835
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE
3200, CHICAGO, IL, 60606
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 2850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated
13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867,
21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325,
46863 and 32252 nucleic acid molecules. The invention also provides
antisense nucleic acid molecules, recombinant expression vectors
containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836,
46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229,
22325, 46863 and 32252 nucleic acid molecules, host cells into which the
expression vectors have been introduced, and nonhuman transgenic animals
in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836,
46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229,
22325, 46863 or 32252 gene has been introduced or disrupted. The
invention still further provides isolated 13237, 18480, 2245, 16228,
7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088,
46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins,
fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228,
7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088,
46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies.
Diagnostic and therapeutic methods utilizing compositions of the
invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:44517 USPATFULL
TI Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836,
46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229,
22325, 46863 and 32252 molecules and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004033509 A1 20040219
AI US 2003-377097 A1 20030228 (10)
RLI Continuation-in-part of Ser. No. US 2001-910150, filed on 18 Jul 2001,
ABANDONED Continuation-in-part of Ser. No. US 2002-251507, filed on 20
Sep 2002, PENDING
PRAI US 2000-219028P 20000718 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15960
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 66 USPATFULL on STN

AB A kit for **prescreening protein concentration**
for crystallization includes a **multiplicity** of vials, a
multiplicity of pre-selected **reagents**, and a
multiplicity of **sample plates**. The
reagents and a corresponding **multiplicity** of
samples of the protein in solutions of varying concentrations
are placed on sample plates. The sample plates containing the reagents
and samples are **incubated**. After **incubation** the
sample plates are examined to determine which of the sample
concentrations are too low and which the sample concentrations are too
high. The sample concentrations that are optimal for protein
crystallization are selected and used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:44191 USPATFULL
TI **Protein crystallography prescreen kit**
IN Segelke, Brent W., San Ramon, CA, UNITED STATES
Krupka, Heike I., Livermore, CA, UNITED STATES
Rupp, Bernhard, Livermore, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2004033181 A1 20040219
AI US 2002-218764 A1 20020814 (10)
DT Utility
FS APPLICATION
LREP Eddie E. Scott, Assistant Laboratory Counsel, Lawrence Livermore
National Laboratory, P.O. Box 808, L-703, Livermore, CA, 94551
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 66 USPATFULL on STN

AB The present invention provides methods and systems for organizing
complex and disparate data. More specifically, the present invention
provides methods and systems for organizing complex and disparate data
into coherent data sets. Coherent data sets resulting from the methods
and systems of the present invention serve as models for biological
systems. Methods and systems for integrating data and creating coherent
data sets are useful for numerous biological applications, such as, for
example, determining gene function, identifying and validating drug and
pesticide targets, identifying and validating drug and pesticide
candidate compounds, profiling drug and pesticide compounds, producing a

compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:32399 USPATFULL
TI Methods and systems for analyzing complex biological systems
IN Zhang, Weiwen, Richland, WA, UNITED STATES
Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES
Davis, Keith, Durham, NC, UNITED STATES
Boyes, Douglas, Chapel Hill, NC, UNITED STATES
Woessner, Jeffrey, Hillsborough, NC, UNITED STATES
Hurban, Patrick, Raleigh, NC, UNITED STATES
Hamilton, Carol, Apex, NC, UNITED STATES
Coffin, Marie, Cary, NC, UNITED STATES
Allen, Keith, Cary, NC, UNITED STATES
Lawrence, Matthew, Rolesville, NC, UNITED STATES
Hoffman, Neil, Chapel Hill, NC, UNITED STATES
Liddell, Craig M., McLean, VA, UNITED STATES
Beecher, Christopher, Chapel Hill, NC, UNITED STATES
PI US 2004024543 A1 20040205
AI US 2002-300184 A1 20021120 (10)
PRAI US 2002-414488P 20020927 (60)
US 2002-408721P 20020906 (60)
US 2002-407840P 20020903 (60)
US 2002-404233P 20020816 (60)
US 2002-384445P 20020530 (60)
US 2002-379562P 20020510 (60)
US 2002-374229P 20020419 (60)
US 2002-372679P 20020415 (60)
US 2002-368776P 20020329 (60)
US 2002-363685P 20020312 (60)
US 2002-356994P 20020214 (60)
US 2001-344953P 20011221 (60)
US 2001-331948P 20011121 (60)
DT Utility
FS APPLICATION
LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528
CLMN Number of Claims: 295
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 7909

L13 ANSWER 14 OF 66 USPATFULL on STN
AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:32151 USPATFULL
TI Methods and systems for analyzing complex biological systems
IN Lawrence, Matthew, Rolesville, NC, UNITED STATES

Zhang, Weiwen, Richland, WA, UNITED STATES
Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES
Davis, Keith, Durham, NC, UNITED STATES
Boyes, Douglas, Chapel Hill, NC, UNITED STATES
Woessner, Jeffrey, Hillsborough, NC, UNITED STATES
Hurban, Patrick, Raleigh, NC, UNITED STATES
Hamilton, Carol, Apex, NC, UNITED STATES
Coffin, Marie, Cary, NC, UNITED STATES
Allen, Keith, Cary, NC, UNITED STATES
Beecher, Christopher, Chapel Hill, NC, UNITED STATES
Hoffman, Neil, Chapel Hill, NC, UNITED STATES
Liddell, Craig M., McLean, VA, UNITED STATES

PI US 2004024293 A1 20040205
AI US 2002-300598 A1 20021120 (10)
PRAI US 2001-331948P 20011121 (60)
US 2001-344953P 20011121 (60)
US 2002-356994P 20020214 (60)
US 2002-363685P 20020312 (60)
US 2002-368776P 20020329 (60)
US 2002-372679P 20020415 (60)
US 2002-374229P 20020419 (60)
US 2002-379562P 20020510 (60)
US 2002-384445P 20020530 (60)
US 2002-404233P 20020816 (60)
US 2002-407840P 20020903 (60)
US 2002-408721P 20020906 (60)
US 2002-414488P 20020927 (60)

DT Utility

FS APPLICATION

LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528

CLMN Number of Claims: 152

ECL Exemplary Claim: 1

DRWN 37 Drawing Page(s)

LN.CNT 7141

L13 ANSWER 15 OF 66 USPATFULL on STN

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:31157 USPATFULL

TI Methods and systems for analyzing complex biological systems

IN Hamilton, Carol, Apex, NC, UNITED STATES

Coffin, Marie, Cary, NC, UNITED STATES

Allen, Keith, Cary, NC, UNITED STATES

Lawrence, Matthew, Rolesville, NC, UNITED STATES

Zhang, Weiwen, Apex, NC, UNITED STATES

Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES

Davis, Keith, Durham, NC, UNITED STATES

Boyes, Douglas, Chapel Hill, NC, UNITED STATES

Woessner, Jeffrey, Hillsborough, NC, UNITED STATES

Hurban, Patrick, Raleigh, NC, UNITED STATES
Hoffman, Neil, Chapel Hill, NC, UNITED STATES
Liddell, Craig M., McLean, VA, UNITED STATES
Beecher, Christopher, Chapel Hill, NC, UNITED STATES

PI US 2004023295 A1 20040205
AI US 2002-300599 A1 20021120 (10)

PRAI US 2002-414488P 20020927 (60)
US 2002-408721P 20020906 (60)
US 2002-407840P 20020903 (60)
US 2002-404233P 20020816 (60)
US 2002-384445P 20020530 (60)
US 2002-379562P 20020510 (60)
US 2002-374229P 20020419 (60)
US 2002-372679P 20020415 (60)
US 2002-368776P 20020329 (60)
US 2002-363685P 20020312 (60)
US 2002-356994P 20020214 (60)
US 2001-344953P 20011221 (60)
US 2001-331948P 20011121 (60)

DT Utility

FS APPLICATION

LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528

CLMN Number of Claims: 296

ECL Exemplary Claim: 1

DRWN 37 Drawing Page(s)

LN.CNT 7486

L13 ANSWER 16 OF 66 USPATFULL on STN

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:25592 USPATFULL

TI Methods and systems for analyzing complex biological systems

IN Winfield, Stephanie, Raleigh, NC, UNITED STATES

Glassbrook, Norman, Chapel Hill, NC, UNITED STATES

Ranasinghe, Yasmin, Southington, CT, UNITED STATES

Broadwell, David, Garner, NC, UNITED STATES

Popa-Burke, Ioana, Durham, NC, UNITED STATES

Nye, Gordon James, Morrisville, NC, UNITED STATES

Beecher, Christopher, Chapel Hill, NC, UNITED STATES

PI US 2004019435 A1 20040129

AI US 2002-300360 A1 20021120 (10)

PRAI US 2002-414488P 20020927 (60)
US 2002-408721P 20020906 (60)
US 2002-407840P 20020903 (60)
US 2002-404233P 20020816 (60)
US 2002-384445P 20020530 (60)
US 2002-379562P 20020510 (60)
US 2002-374229P 20020419 (60)
US 2002-372679P 20020415 (60)

US 2002-368776P 20020329 (60)
US 2002-363685P 20020312 (60)
US 2002-356994P 20020214 (60)
US 2001-344953P 20011221 (60)
US 2001-331948P 20011121 (60)
DT Utility
FS APPLICATION
LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528
CLMN Number of Claims: 233
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 7507

L13 ANSWER 17 OF 66 USPATFULL on STN

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:25587 USPATFULL

TI Methods and systems for analyzing complex biological systems

IN Hurban, Patrick, Raleigh, NC, UNITED STATES

Hamilton, Carol, Apex, NC, UNITED STATES

Coffin, Marie, Cary, NC, UNITED STATES

Allen, Keith, Cary, NC, UNITED STATES

Lawrence, Matthew, Rolesville, NC, UNITED STATES

Zhang, Weiwen, Richland, WA, UNITED STATES

Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES

Davis, Keith, Durham, NC, UNITED STATES

Boyes, Douglas, Chapel Hill, NC, UNITED STATES

Woessner, Jeffrey, Hillsborough, NC, UNITED STATES

Beecher, Christopher, Chapel Hill, NC, UNITED STATES

Hoffman, Neil, Chapel Hill, NC, UNITED STATES

Liddell, Craig M., McLean, VA, UNITED STATES

PI US 2004019430 A1 20040129

AI US 2002-300291 A1 20021120 (10)

PRAI US 2002-414488P 20020927 (60)

US 2002-408721P 20020906 (60)

US 2002-407840P 20020903 (60)

US 2002-404233P 20020816 (60)

US 2002-384445P 20020530 (60)

US 2002-379562P 20020510 (60)

US 2002-374229P 20020419 (60)

US 2002-372679P 20020415 (60)

US 2002-368776P 20020329 (60)

US 2002-363685P 20020312 (60)

US 2002-356994P 20020214 (60)

US 2001-344953P 20011221 (60)

US 2001-331948P 20011121 (60)

DT Utility

FS APPLICATION

LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,

27709-4528

CLMN Number of Claims: 152
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 7064

L13 ANSWER 18 OF 66 USPTAFULL on STN

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:25586 USPTAFULL

TI Methods and systems for analyzing complex biological systems

IN Coffin, Marie, Cary, NC, UNITED STATES

Allen, Keith, Cary, NC, UNITED STATES

Lawrence, Matthew, Rolesville, NC, UNITED STATES

Zhang, Weiwen, Richland, WA, UNITED STATES

Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES

Davis, Keith, Durham, NC, UNITED STATES

Boyes, Douglas, Chapel Hill, NC, UNITED STATES

Woessner, Jeffrey, Hillsborough, NC, UNITED STATES

Hurban, Patrick M., Raleigh, NC, UNITED STATES

Hamilton, Carol, Apex, NC, UNITED STATES

Hoffman, Neil, Chapel Hill, NC, UNITED STATES

Liddell, Craig M., McLean, VA, UNITED STATES

Beecher, Christopher, Chapel Hill, NC, UNITED STATES

PI US 2004019429 A1 20040129

AI US 2002-300166 A1 20021120 (10)

PRAI US 2002-414488P 20020927 (60)

US 2002-408721P 20020906 (60)

US 2002-407840P 20020903 (60)

US 2002-404233P 20020816 (60)

US 2002-384445P 20020530 (60)

US 2002-379562P 20020510 (60)

US 2002-374229P 20020419 (60)

US 2002-372679P 20020415 (60)

US 2002-368776P 20020329 (60)

US 2002-363685P 20020312 (60)

US 2002-356994P 20020214 (60)

US 2001-344953P 20011221 (60)

US 2001-331948P 20011121 (60)

DT Utility

FS APPLICATION

LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528

CLMN Number of Claims: 152

ECL Exemplary Claim: 1

DRWN 37 Drawing Page(s)

LN.CNT 7228

L13 ANSWER 19 OF 66 USPTAFULL on STN

AB The present invention provides methods and systems for organizing

complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:24662 USPATFULL

TI Methods and systems for analyzing complex biological systems

IN Allen, Keith, Cary, NC, UNITED STATES

Lawrence, Matthew, Rolesville, NC, UNITED STATES

Zhang, Weiwen, Richland, WA, UNITED STATES

Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES

Davis, Keith, Durham, NC, UNITED STATES

Boyes, Douglas, Chapel Hill, NC, UNITED STATES

Woessner, Jeffrey, Hillsborough, NC, UNITED STATES

Hurban, Patrick, Raleigh, NC, UNITED STATES

Hamilton, Carol, Apex, NC, UNITED STATES

Coffin, Marie, Cary, NC, UNITED STATES

Liddell, Craig M., McLean, VA, UNITED STATES

Beecher, Christopher, Chapel Hill, NC, UNITED STATES

Hoffman, Neil, Chapel Hill, NC, UNITED STATES

PI US 2004018501 A1 20040129

AI US 2002-300551 A1 20021120 (10)

PRAI US 2002-414488P 20020927 (60)

US 2002-408721P 20020906 (60)

US 2002-407840P 20020903 (60)

US 2002-404233P 20020816 (60)

US 2002-384445P 20020530 (60)

US 2002-379562P 20020510 (60)

US 2002-374229P 20020419 (60)

US 2002-372679P 20020415 (60)

US 2002-368776P 20020329 (60)

US 2002-363685P 20020312 (60)

US 2002-356994P 20020214 (60)

US 2001-344953P 20011221 (60)

US 2001-331948P 20011121 (60)

DT Utility

FS APPLICATION

LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC, 27709-4528

CLMN Number of Claims: 296

ECL Exemplary Claim: 1

DRWN 37 Drawing Page(s)

LN.CNT 7756

L13 ANSWER 20 OF 66 USPATFULL on STM

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide

candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:24661 USPATFULL
TI Methods and systems for analyzing complex biological systems
IN Glassbrook, Norman, Chapel Hill, NC, UNITED STATES
Winfield, Stephanie, Raleigh, NC, UNITED STATES
Beecher, Christopher, Chapel Hill, NC, UNITED STATES
Ranasinghe, Yasmin, Southington, CT, UNITED STATES
Broadwell, David, Garner, NC, UNITED STATES
Popa-Burke, Ioana, Durham, NC, UNITED STATES
Nye, Gordon James, Morrisville, NC, UNITED STATES
PI US 2004018500 A1 20040129
AI US 2002-300543 A1 20021120 (10)
PRAI US 2001-331948P 20011121 (60)
US 2001-344953P 20011221 (60)
US 2002-356994P 20020214 (60)
US 2002-363685P 20020312 (60)
US 2002-368776P 20020329 (60)
US 2002-372679P 20020415 (60)
US 2002-374229P 20020419 (60)
US 2002-379562P 20020510 (60)
US 2002-384445P 20020530 (60)
US 2002-404233P 20020816 (60)
US 2002-407840P 20020903 (60)
US 2002-408721P 20020906 (60)
US 2002-414488P 20020927 (60)
DT Utility
FS APPLICATION
LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528
CLMN Number of Claims: 233
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 7492

L13 ANSWER 21 OF 66 USPATFULL on STN
AB The invention provides isolated nucleic acids molecules, designated
25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937,
49931 and 49933 nucleic acid molecules. The invention also provides
antisense nucleic acid molecules, recombinant expression vectors
containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816,
16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into
which the expression vectors have been introduced, and nonhuman
transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692,
46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or
disrupted. The invention still further provides isolated 25869, 25934,
26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933
proteins, fusion proteins, antigenic peptides and anti-25869, 25934,
26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933
antibodies. Diagnostic and therapeutic methods utilizing compositions of
the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:12981 USPATFULL
TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839,
49937, 49931 and 49933 molecules and uses therefor
IN Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004009501 A1 20040115

US 2004157221 A9 20040812

AI US 2003-377072 A1 20030227 (10)

RLI Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001,
PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov
2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on
25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser.
No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part
of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING
Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001,
ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17
Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291,
filed on 21 Aug 2001, ABANDONED

PRAI US 2000-215370P 20000629 (60)

US 2000-187455P 20000307 (60)

US 2000-199801P 20000426 (60)

US 2000-205508P 20000519 (60)

US 2000-213688P 20000623 (60)

US 2000-218675P 20000717 (60)

US 2000-250932P 20001130 (60)

US 2000-226504P 20000821 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 16123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 22 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated
26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565,
13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The
invention also provides antisense nucleic acid molecules, recombinant
expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764,
62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic
acid molecules, host cells into which the expression vectors have been
introduced, and nonhuman transgenic animals in which a 26199, 33530,
33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911,
86216, 25206 or 8843 gene has been introduced or disrupted. The
invention still further provides isolated 26199, 33530, 33949, 47148,
50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or
8843 proteins, fusion proteins, antigenic peptides and anti-26199,
33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305,
14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic
methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:7430 USPATFULL

TI Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235,
23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES

MacBeth, Kyle J., Boston, MA, UNITED STATES

Curtis, Rory A. J., Ashland, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

Weich, Nadine S., Brookline, MA, UNITED STATES

Olandt, Peter J., Buffalo, NY, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004005664 A1 20040108

AI US 2003-410764 A1 20030410 (10)

RLI Continuation-in-part of Ser. No. US 2001-924358, filed on 6 Aug 2001,
PENDING Continuation-in-part of Ser. No. US 2003-350553, filed on 24 Jan
2003, PENDING Continuation-in-part of Ser. No. US 2001-966614, filed on
27 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2002-281094,
filed on 25 Oct 2002, PENDING Continuation-in-part of Ser. No. US
2002-76535, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser.
No. US 2001-860352, filed on 17 May 2001, ABANDONED Continuation-in-part
of Ser. No. US 2000-593927, filed on 15 Jun 2000, ABANDONED
Continuation-in-part of Ser. No. US 2002-226410, filed on 23 Aug 2002,
PENDING Continuation-in-part of Ser. No. US 2001-997816, filed on 29 Nov
2001, ABANDONED Continuation-in-part of Ser. No. US 2000-686673, filed
on 11 Oct 2000, PENDING

PRAI US 2000-229300P 20000901 (60)

US 2002-351572P 20020124 (60)

US 2000-238054P 20001005 (60)

US 2001-347815P 20011029 (60)

US 2001-269440P 20010216 (60)

US 2000-205301P 20000519 (60)

US 2000-199391P 20000425 (60)

US 2001-314884P 20010824 (60)

US 2000-250186P 20001130 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 17049

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 66 USPATFULL on STM

AB Biospecific desorption microflow systems and methods employing
immobilized prebound members of a binding pair are disclosed are used in
detecting analytes in samples, identifying binding sites and studying
biospecific interactions and their inhibitors on intact cells, cell
membranes, cell organelles, cell fragments, proteins, and other
biopolymers. The microflow reaction channel is in fluid connection with
one or more reservoirs each having a means for transporting fluids or
sample to a microflow channel having a prebound binding pair. The
biospecifically desorbed labeled molecules may be continuously detected
and quantitated on-line. Apparent dissociation constants and IC50 values
(for inhibitors) may be computed automatically. Fluorescent,
luminescent, or electrogenic labels may be used to provide continuous
flow microsystems having subpicomole sensitivities. Using microfluidic
arrays, a single **sample** may be analyzed for the presence of
multiple functional binding sites simultaneously. The method
finds use as a universal technique for mapping the surfaces of proteins
(epitope mapping) and other biopolymers for functional binding elements.
The method is especially suitable for the functional analysis of the
multitude of consensus sequences that are emerging from genome programs
(for verification that a binding site predicted from a genome sequence
is indeed functional) and for studying biospecific interactions that
occur in the extracellular environment e.g. blood
coagulation/fibrinolysis, inflammation, cell migration, bone biology,
tissue and organ formation and regrowth. The method is well suited for

studying biospecific interaction in an automated and highly controlled manner and for rapidly screening drug candidates for blocking these interactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:7348 USPATFULL
TI Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators
IN Shipwash, Edward, San Francisco, CA, UNITED STATES
PA NanoBioDynamics, Incorporated, San Jose, CA (U.S. corporation)
PI US 2004005582 A1 20040108
AI US 2002-327531 A1 20021219 (10)
RLI Continuation-in-part of Ser. No. US 2001-927424, filed on 9 Aug 2001, PENDING
PRAI US 2001-343025P 20011219 (60)
US 2000-224551P 20000810 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 4906
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 66 USPATFULL on STN

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2004:2818 USPATFULL
TI Methods and systems for analyzing complex biological systems
IN Woessner, Jeffrey, Hillsborough, NC, UNITED STATES
Hurban, Patrick, Raleigh, NC, UNITED STATES
Hamilton, Carol, Apex, NC, UNITED STATES
Coffin, Marie, Cary, NC, UNITED STATES
Allen, Keith, Cary, NC, UNITED STATES
Lawrence, Matthew, Rolesville, NC, UNITED STATES
Zhang, Weiwen, Richland, WA, UNITED STATES
Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES
Davis, Keith, Durham, NC, UNITED STATES
Boyes, Douglas, Chapel Hill, NC, UNITED STATES
Liddell, Craig M., McLean, VA, UNITED STATES
Beecher, Christopher, Chapel Hill, NC, UNITED STATES
Hoffman, Neil, Chapel Hill, NC, UNITED STATES
PI US 2004002842 A1 20040101
AI US 2002-300204 A1 20021120 (10)
PRAI US 2002-414488P 20020927 (60)
US 2002-408721P 20020906 (60)
US 2002-407840P 20020903 (60)
US 2002-404233P 20020816 (60)

US 2002-384445P 20020530 (60)
US 2002-379562P 20020510 (60)
US 2002-374229P 20020419 (60)
US 2002-372679P 20020415 (60)
US 2002-368776P 20020329 (60)
US 2002-363685P 20020312 (60)
US 2002-356994P 20020214 (60)
US 2001-344953P 20011221 (60)
US 2001-331948P 20011121 (60)

DT Utility

FS APPLICATION

LREP PARADIGM GENETICS, INC., 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528

CLMN Number of Claims: 296

ECL Exemplary Claim: 1

DRWN 37 Drawing Page(s)

LN.CNT 7614

L13 ANSWER 25 OF 66 USPATFULL on STN

AB The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropatterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:337801 USPATFULL

TI Machine readable storage media for detecting distribution of macromolecules between nucleus and cytoplasm in cells

IN Dunlay, R. Terry, Pittsburgh, PA, United States
Taylor, D. Lansing, Pittsburgh, PA, United States
Gough, Albert H., Pittsburgh, PA, United States
Giuliano, Kenneth A., Pittsburgh, PA, United States

PA Cellomics, Inc., Pittsburgh, PA, United States (U.S. corporation)

PI US 6671624 B1 20031230

AI US 2000-724376 20001127 (9)

RLI Continuation-in-part of Ser. No. US 1997-865341, filed on 29 May 1997, now patented, Pat. No. US 6103479 Continuation-in-part of Ser. No. US 1997-810983, filed on 27 Feb 1997, now patented, Pat. No. US 5989835

PRAI US 1997-69246P 19971211 (60)

US 1997-69329P 19971211 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Smith, Carolyn L

LREP McDonnell Boehnen Hulbert & Berghoff, Harper, David S.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 24 Drawing Figure(s); 24 Drawing Page(s)

LN.CNT 2863

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 26 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, and 8105 nucleic acid molecules, which encode novel human calcium channel family members, human sodium ion channel family members, human potassium channel family members, human sodium-sugar symporter family members, human ABC transporter family members, human cation family members, and human sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 gene has been introduced or disrupted. The invention still further provides isolated 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 proteins, fusion proteins, antigenic peptides and anti-52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:330125 USPATFULL

TI Novel human ion channel and transporter family members

IN Curtis, Rory A. J., Framingham, MA, UNITED STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES

Gu, Wei, Brookline, MA, UNITED STATES

PI US 2003232336 A1 20031218

AI US 2002-162102 A1 20020604 (10)

RLI Continuation-in-part of Ser. No. US 2001-875321, filed on 6 Jun 2001,
PENDING Continuation-in-part of Ser. No. WO 2001-US18340, filed on 6 Jun
2001, PENDING

PRAI WO 2001-US18340 20010606
WO 2001-US18398 20010605
WO 2001-US18247 20010605
WO 2001-US25474 20010815
WO 2001-US26096 20010821
WO 2002-US9728 20020328
US 2001-290288P 20010511 (60)
US 2001-279281P 20010328 (60)
US 2000-226770P 20000821 (60)
US 2000-227068P 20000822 (60)
US 2000-209845P 20000606 (60)

DT Utility

FS APPLICATION

LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney
Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 40 Drawing Page(s)

LN.CNT 38135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 27 OF 66 USPATFULL on STN

AB The present invention provides methods and systems for organizing complex and disparate data. More specifically, the present invention provides methods and systems for organizing complex and disparate data into coherent data sets. Coherent data sets resulting from the methods and systems of the present invention serve as models for biological systems. Methods and systems for integrating data and creating coherent data sets are useful for numerous biological applications, such as, for example, determining gene function, identifying and validating drug and pesticide targets, identifying and validating drug and pesticide candidate compounds, profiling drug and pesticide compounds, producing a compilation of health or wellness profiles, determining compound site(s) of action, identifying unknown samples, and numerous other applications

in the agricultural, pharmaceutical, forensic, and biotechnology industries.

AN 2003:325467 USPATFULL
TI Methods and systems for analyzing complex biological systems
IN Hamilton, Carol, Apex, NC, UNITED STATES
Woessner, Jeffrey, Hillsborough, NC, UNITED STATES
Hurban, Patrick, Raleigh, NC, UNITED STATES
Coffin, Marie, Cary, NC, UNITED STATES
Allen, Keith, Cary, NC, UNITED STATES
Lawrence, Matthew, Rolesville, NC, UNITED STATES
Zhang, Weiwen, Richland, WA, UNITED STATES
Shuster, Jeffrey, Chapel Hill, NC, UNITED STATES
Davis, Keith, Durham, NC, UNITED STATES
Boyes, Douglas, Chapel Hill, NC, UNITED STATES
Hoffman, Neil, Chapel Hill, NC, UNITED STATES
Liddell, Craig M., McLean, VA, UNITED STATES
Beecher, Christopher, Chapel Hill, NC, UNITED STATES

PI US 2003229451 A1 20031211
AI US 2002-300262 A1 20021120 (10)
PRAI US 2002-414488P 20020927 (60)
US 2002-408721P 20020906 (60)
US 2002-407840P 20020903 (60)
US 2002-404233P 20020816 (60)
US 2002-384445P 20020530 (60)
US 2002-379562P 20020510 (60)
US 2002-374229P 20020419 (60)
US 2002-372679P 20020415 (60)
US 2002-368776P 20020329 (60)
US 2002-363685P 20020312 (60)
US 2002-356994P 20020214 (60)
US 2001-344953P 20011221 (60)
US 2001-331948P 20011121 (60)

DT Utility
FS APPLICATION
LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528
CLMN Number of Claims: 152
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 7094

L13 ANSWER 28 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:318632 USPATFULL

TI Novel human transferase family members and uses thereof
 IN Meyers, Rachel E., Newton, MA, UNITED STATES
 Williamson, Mark, Saugus, MA, UNITED STATES
 Leiby, Kevin R., Natick, MA, UNITED STATES
 Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
 Olandt, Peter J., Newton, MA, UNITED STATES
 MacBeth, Kyle J., Boston, MA, UNITED STATES
 Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
 Tsai, Fong-Ying, Newton, MA, UNITED STATES
 Hunter, John J., Somerville, MA, UNITED STATES
 PI US 2003224376 A1 20031204
 AI US 2002-184648 A1 20020627 (10)
 RLI Continuation-in-part of Ser. No. US 2001-815028, filed on 22 Mar 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-801220, filed on 7 Mar
 2001, PENDING Continuation-in-part of Ser. No. US 2001-816714, filed on
 23 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-844948,
 filed on 27 Apr 2001, PENDING Continuation-in-part of Ser. No. US
 2001-861164, filed on 18 May 2001, ABANDONED Continuation-in-part of
 Ser. No. US 2001-883060, filed on 15 Jun 2001, PENDING
 Continuation-in-part of Ser. No. US 2001-962678, filed on 25 Sep 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-973457, filed on 9 Oct
 2001, PENDING Continuation-in-part of Ser. No. US 2002-72285, filed on 8
 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-817910, filed
 on 26 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-842528,
 filed on 25 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US
 2001-882836, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser.
 No. US 2001-882872, filed on 15 Jun 2001, ABANDONED
 PRAI WO 2001-US9358 20010322
 WO 2001-US7269 20010307
 WO 2001-US9468 20010323
 WO 2001-US13805 20010427
 WO 2001-US16292 20010518
 WO 2001-US19138 20010615
 WO 2001-US29963 20010925
 WO 2002-US3736 20020208
 WO 2001-US9633 20010326
 WO 2001-US40607 20010425
 WO 2001-US19543 20010615
 WO 2001-US19153 20010615
 US 2000-191964P 20000324 (60)
 US 2000-187456P 20000307 (60)
 US 2000-191865P 20000324 (60)
 US 2000-200604P 20000428 (60)
 US 2000-205408P 20000519 (60)
 US 2000-212079P 20000615 (60)
 US 2000-235044P 20000925 (60)
 US 2000-238849P 20001006 (60)
 US 2001-267494P 20010208 (60)
 US 2000-192092P 20000324 (60)
 US 2000-199500P 20000425 (60)
 US 2000-211730P 20000615 (60)
 US 2000-212077P 20000615 (60)
 DT Utility
 FS APPLICATION
 LREP Theodore R. Allen, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
 Cambridge, MA, 02139
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 125 Drawing Page(s)
 LN.CNT 66695
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:306426 USPATFULL

TI Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor

IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003215860 A1 20031120

AI US 2003-407079 A1 20030403 (10)

RLI Continuation-in-part of Ser. No. US 2002-226102, filed on 22 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225094, filed on 21 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-272417, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 2000-715790, filed on 17 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-282837, filed on 29 Oct 2002, PENDING Continuation of Ser. No. US 2001-796338, filed on 28 Feb 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-863200, filed on 22 May 2001, ABANDONED

PRAI US 2001-314041P 20010822 (60)

US 2001-314185P 20010822 (60)

US 2000-191845P 20000324 (60)

US 2000-186059P 20000229 (60)

US 2000-206019P 20000522 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 12157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 30 OF 66 USPATFULL on STN

AB A method for identifying a product involves the steps of: (1) associating with the product a marker ligand; and (2) detecting the marker ligand in the product at a later point in time as a means of identifying the product by contacting the product with a detector composition. The detector composition comprises one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter. The method may also employ a corepressor or coactivator or a nucleotide sequence encoding the corepressor or activator.

Interaction between the marker ligand and ligand binding domain is highly specific and induces a change in the expression of the reporter gene, the change producing a detectable signal identifying the presence of the marker ligand in the product. The detector composition, a cell line containing the first and second nucleotide sequences, kits using them and products marked with specific marker ligands are useful in this method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:288602 USPATFULL
TI Methods for identifying products employing gene expression
IN Weinstein, Barry, Dresher, PA, UNITED STATES
Keller, Lorraine Holowach, Lansdale, PA, UNITED STATES
Palli, Subba Reddy, Lansdale, PA, UNITED STATES
PI US 2003203360 A1 20031030
AI US 2001-950312 A1 20010910 (9)
RLI Division of Ser. No. US 2000-690391, filed on 17 Oct 2000, GRANTED, Pat. No. US 6576422
DT Utility
FS APPLICATION
LREP New RheoGene I LLC, 2650 Eisenhower Avenue, Norristown, PA, 19403
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 31 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:257879 USPATFULL
TI Novel human protein kinase, phosphatase, and protease family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
PI US 2003180930 A1 20030925
AI US 2002-170789 A1 20020613 (10)
RLI Continuation-in-part of Ser. No. US 2001-797039, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-882166, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-934406, filed on

21 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-861801,
filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. US
2001-801267, filed on 6 Mar 2001, PENDING Continuation-in-part of Ser.
No. US 2001-829671, filed on 10 Apr 2001, PENDING Continuation-in-part
of Ser. No. US 2001-961721, filed on 24 Sep 2001, PENDING
Continuation-in-part of Ser. No. US 2001-45367, filed on 7 Nov 2001,
PENDING Continuation-in-part of Ser. No. US 2001-801275, filed on 6 Mar
2001, PENDING

PRAI WO 2001-US6525 20010228
WO 2001-US19269 20010615
WO 2001-US26052 20010821
WO 2001-US16549 20010521
WO 2001-US71138 20010305
WO 2001-US40483 20010411
WO 2001-US29904 20010924
WO 2001-US7074 20010305
US 2000-186061P 20000229 (60)
US 2000-212078P 20000615 (60)
US 2000-226740P 20000821 (60)
US 2000-205508P 20000519 (60)
US 2000-187454P 20000307 (60)
US 2000-197508P 20000418 (60)
US 2000-235023P 20000925 (60)
US 2000-246561P 20001107 (60)
US 2000-187420P 20000307 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 62 Drawing Page(s)

LN.CNT 45159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 32 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated
58566 nucleic acid molecules, which encode novel anion exchanger family
members. The invention also provides antisense nucleic acid molecules,
recombinant expression vectors containing 58566 nucleic acid molecules,
host cells into which the expression vectors have been introduced, and
nonhuman transgenic animals in which a 58566 gene has been introduced or
disrupted. The invention still further provides isolated 58566 proteins,
fusion proteins, antigenic peptides and anti-58566 antibodies.
Diagnostic and therapeutic methods utilizing compositions of the
invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:238734 USPATFULL

TI 58566, a human anion exchanger family member and uses therefor

IN Curtis, Rory A.J., Farmingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003166892 A1 20030904

AI US 2002-128202 A1 20020423 (10)

PRAI US 2001-286029P 20010424 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 5263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 33 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:238067 USPATFULL
TI 18232, a novel dual specificity phosphatase and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., a Delaware corporation (U.S. corporation)
PI US 2003166224 A1 20030904
AI US 2002-165272 A1 20020607 (10)
RLI Continuation of Ser. No. US 2000-704139, filed on 1 Nov 2000, GRANTED, Pat. No. US 6420153
PRAI US 2000-185772P 20000229 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 34 OF 66 USPATFULL on STN

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:237907 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003166064 A1 20030904
AI US 2002-99926 A1 20020314 (10)
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul

2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)

DT Utility
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 35 OF 66 USPATFULL on STN

AB The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:220740 USPATFULL

TI Methods and compositions for diagnosing and treating rheumatoid arthritis

IN Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES
Trepicchio, William L., Andover, MA, UNITED STATES

PI US 2003154032 A1 20030814

AI US 2001-23451 A1 20011217 (10)

PRAI US 2000-255861P 20001215 (60)

DT Utility

FS APPLICATION

LREP Patent Group, FOLEY, HOAG & ELIOT LLP, One Post Office Square, Boston, MA, 02109

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 25385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 36 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted. The invention still further provides isolated 20716, 65494, 44576, 1983,

52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 proteins, fusion proteins, antigenic peptides and anti-20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:200905 USPTFULL
TI Novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2003138890 A1 20030724
AI US 2002-145586 A1 20020514 (10)
RLI Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb 2001, PENDING
PRAI WO 2001-US6057 20010223
WO 2001-US23152 20010723
WO 2001-US40476 20010409
WO 2001-US7139 20010305
WO 2001-US19544 20010615
WO 2001-US29967 20010925
WO 2001-US9470 20010323
WO 2001-US10380 20010330
WO 2001-US29968 20010925
US 2000-186059P 20000229 (60)
US 2000-220042P 20000721 (60)
US 2000-187447P 20000307 (60)
US 2000-211673P 20000615 (60)
US 2000-235049P 20000925 (60)
US 2000-191863P 20000324 (60)
US 2000-193919P 20000331 (60)
US 2000-235032P 20000925 (60)
DT Utility
FS APPLICATION
LREP JOHN W. FREEMAN, ESQ., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 97 Drawing Page(s)
LN.CNT 51652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 37 OF 66 USPTFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted. The invention still further provides isolated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234,

21617, 55562, 23566, 33489, or 57779 proteins, fusion proteins, antigenic peptides and anti-47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:188692 USPATFULL
TI Novel human genes and methods of use thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2003130485 A1 20030710
AI US 2002-176306 A1 20020620 (10)
RLI Continuation-in-part of Ser. No. US 2001-1137, filed on 14 Nov 2001,
PENDING Continuation-in-part of Ser. No. WO 2001-US45291, filed on 14
Nov 2001, PENDING
PRAI WO 2001-US49416 20011218
WO 2001-US46717 20011022
US 2000-248362P 20001114 (60)
US 2000-248331P 20001114 (60)
US 2000-248365P 20001114 (60)
US 2000-250077P 20001130 (60)
US 2000-250327P 20001130 (60)
US 2000-250176P 20001130 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 60 Drawing Page(s)
LN.CNT 26835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 38 OF 66 USPATFULL on STN

AB Systems, methods, and apparatus for screening libraries, particularly
display libraries are disclosed. Methods can be automated or at least
partially machine-based. Also disclosed are software and databases that
interface with a library screening process such as a display library
screening process. A computer system can be used to store, manage, and
generate information that includes assay results and sample tracking
from various automation stations. The system can include interfaces for
project management, data analysis, and sample tracking and auditing. A
database can manage hits identified during screening of a library. The
database can be a relational database that includes tables for projects,
libraries, screens, and hits.

AN 2003:187869 USPATFULL
TI Library screening
IN Whelihan, E. Fayelle, South Boston, MA, UNITED STATES
Ladner, Robert C., Ijamsville, MD, UNITED STATES
PI US 2003129659 A1 20030710
AI US 2002-309391 A1 20021203 (10)
PRAI US 2001-337482P 20011203 (60)
US 2001-336672P 20011205 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 54
ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)
LN.CNT 3430

L13 ANSWER 39 OF 66 USPATFULL on STN

AB A method for identifying a product involves the steps of: (1) associating with the product a marker ligand; and (2) detecting the marker ligand in the product at a later point in time as a means of identifying the product by contacting the product with a detector composition. The detector composition comprises one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter. The method may also employ a corepressor or coactivator or a nucleotide sequence encoding the corepressor or activator. Interaction between the marker ligand and ligand binding domain is highly specific and induces a change in the expression of the reporter gene, the change producing a detectable signal identifying the presence of the marker ligand in the product. The detector composition, a cell line containing the first and second nucleotide sequences, kits using them and products marked with specific marker ligands are useful in this method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:155558 USPATFULL
TI Method for identifying products employing gene expression
IN Weinstein, Barry, Dreshner, PA, United States
Keller, Lorraine Holowach, Lansdale, PA, United States
Palli, Subba Reddy, Lansdale, PA, United States
PA Rohm and Haas Company, Philadelphia, PA, United States (U.S. corporation)
PI US 6576422 B1 20030610
AI US 2000-690391 20001017 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Chakrabarti, Arun Kr.
LREP Jolly-Tornetta, Camille, Rogerson, Thomas D., Rondinelli, Rachel H.
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1341

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 40 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 21132 nucleic acid molecules, which encode novel GPCR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21132 gene has been introduced or disrupted. The invention still further provides isolated 21132 proteins, fusion proteins, antigenic peptides and anti-21132 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:140941 USPATFULL
TI 21132, a human G-protein coupled receptor family member and uses therefor
IN Carroll, Joseph M., Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003096783 A1 20030522
AI US 2002-266886 A1 20021008 (10)
PRAI US 2001-328345P 20011010 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 4722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 41 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid molecules, which encode novel human membrane-associated protein family members, and human cell surface protein family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or disrupted. The invention still further provides isolated 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins, antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:140464 USPATFULL
TI Novel human membrane-associated protein and cell surface protein family members
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES
PI US 2003096305 A1 20030522
AI US 2002-162435 A1 20020604 (10)
RLI Continuation-in-part of Ser. No. US 2001-836499, filed on 17 Apr 2001, PENDING
PRAI WO 2001-US12420 20010417
WO 2001-US19963 20010625
WO 2001-US16013 20010518
WO 2001-US20055 20010621
WO 2002-US275 20020108
WO 2001-US41811 20010821
US 2000-197507P 20000418 (60)
US 2000-214220P 20000623 (60)
US 2000-205674P 20000519 (60)
US 2000-213963P 20000623 (60)
US 2001-260286P 20010108 (60)
US 2000-226612P 20000821 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 30445

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 42 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:134569 USPATFULL
TI Novel human enzyme family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2003092658 A1 20030515
AI US 2002-175696 A1 20020620 (10)
RLI Continuation-in-part of Ser No. US 2002-67668, filed on 4 Feb 2002,
PENDING
PRAI US 2001-266140P 20010202 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney
Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 21384

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 43 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 18636 nucleic acid molecules, which encode novel G protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636 gene has been introduced or disrupted. The invention still further provides isolated 18636 proteins, fusion proteins, antigenic peptides and anti-18636 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:127069 USPATFULL
TI 18636 receptor, a human G-protein-coupled receptor (GPCR) family member,
and uses therefor
IN Carroll, Joseph M., Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003087281 A1 20030508
AI US 2002-226102 A1 20020822 (10)
PRAI US 2001-314041P 20010822 (60)
DT Utility
FS APPLICATION

LREP Steven A. Bossone, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4612

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 44 OF 66 USPATFULL on STN

AB A device for biomedical research contains a flat solid support and a plurality of proteins, with the proteins immobilized on the support at pre-determined positions. The proteins immobilized at each position can be different but share a common property. An interactive protein array is produced when proteins that interact with a ligand are immobilized at a position and proteins interact with another ligand are immobilized at another position on the flat support. The interactive protein arrays are produced either by isolating interacting proteins sequentially or simultaneously. Chemical covalent cross-linking is used to stabilize the protein complexes on the array and to immobilize the proteins on the flat support. The devices are used in studying proteins, particularly in identifying protein-protein interactions and their modulators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:120079 USPATFULL
TI Method of making interactive protein arrays
IN Wang, Yingjian, New Britain, CT, UNITED STATES
PI US 2003082560 A1 20030501
AI US 2001-55838 A1 20011029 (10)
DT Utility
FS APPLICATION
LREP Yingjian Wang, 1 Peace Court, New Britain, CT, 06051
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1102

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 45 OF 66 USPATFULL on STN

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)

US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 46 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:93080 USPATFULL

TI Novel nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor

IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

Meyers, Rachel E., Newton, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003064439 A1 20030403

AI US 2002-164966 A1 20020607 (10)

RLI Continuation-in-part of Ser. No. US 2001-34864, filed on 27 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-996194, filed on 28 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-908928, filed on 19 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-908180, filed on 18 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-887389, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-789300, filed on 20 Feb 2001, GRANTED, Pat. No. US 6458576

PRAI US 2000-258517P 20001228 (60)

US 2000-250348P 20001130 (60)

US 2000-250073P 20001130 (60)

US 2000-253878P 20001129 (60)

US 2000-250338P 20001130 (60)

US 2000-220465P 20000720 (60)

US 2000-219740P 20000720 (60)

US 2000-214138P 20000626 (60)

US 2000-183208P 20000217 (60)

DT Utility

FS APPLICATION

LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 63 Drawing Page(s)

LN.CNT 27929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 47 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 2466 nucleic acid molecules, which encode a G protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2466 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2466 gene has been introduced or disrupted. The invention still further provides isolated 2466 proteins, fusion proteins, antigenic peptides and anti-2466 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:93040 USPATFULL

TI 2466 receptor, a human G-protein-coupled receptor (GPCR) family member and uses therefor

IN Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003064399 A1 20030403

AI US 2002-225094 A1 20020821 (10)

PRAI US 2001-314185P 20010822 (60)

DT Utility

FS APPLICATION

LREP Steven A. Bossone, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LN.CNT 4590

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 48 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 26030 nucleic acid molecules, which encode a novel rhoGAP family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26030 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26030 gene has been introduced or disrupted. The invention still further provides isolated 26030 proteins, fusion proteins, antigenic peptides and anti-26030 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:79306 USPATFULL

TI 26030, a human rho-GAP family member and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003055234 A1 20030320

AI US 2002-132585 A1 20020425 (10)

PRAI US 2001-286581P 20010425 (60)

DT Utility

FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4286

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 49 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 23228 nucleic acid molecules, which encode novel tetraspanin members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23228 gene has been introduced or disrupted. The invention still further provides isolated 23228 proteins, fusion proteins, antigenic peptides and anti-23228 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:307862 USPATFULL
TI 23228, a novel human tetraspanin family member and uses thereof
IN Leiby, Kevin R., Natick, MA, UNITED STATES
PI US 2002172986 A1 20021121
AI US 2001-934268 A1 20010821 (9)
PRAI US 2000-226612P 20000821 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4888

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 50 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 33521 nucleic acid molecules, which encode novel Rho GEF members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33521 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33521 gene has been introduced or disrupted. The invention still further provides isolated 33521 proteins, fusion proteins, antigenic peptides and anti-33521 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:295100 USPATFULL
TI 33521, a novel human guanine nucleotide exchange family member and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PI US 2002165145 A1 20021107
AI US 2001-963959 A1 20010925 (9)
PRAI US 2000-235033P 20000925 (60)
DT Utility
FS APPLICATION
LREP Louis Myers, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5581

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 51 OF 66 USPATFULL on STN

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions

thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 52 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 33945 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33945 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33945 gene has been introduced or disrupted. The invention still further provides isolated 33945 proteins, fusion proteins, antigenic peptides and anti-33945 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:258856 USPATFULL
TI 33945, a human glycosyltransferase family member and uses therefor
IN Olandt, Peter J., East Boston, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PI US 2002142426 A1 20021003
AI US 2002-74527 A1 20020212 (10)
PRAI US 2001-269202P 20010215 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4739

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 53 OF 66 USPATFULL on STN

AB Compositions and methods for the therapy and diagnosis of cancer,

particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002132237 A1 20020919
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 54 OF 66 USPATFULL on STN

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:242791 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2002131971 A1 20020919
AI US 2001-33528 A1 20011226 (10)
RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001,
PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 55 OF 66 USPTFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 33449 nucleic acid molecules, which encode novel protease or S26 signal peptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33449 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33449 gene has been introduced or disrupted. The invention still further provides isolated 33449 proteins, fusion proteins, antigenic peptides and anti-33449 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:214242 USPTFULL
TI 33449, a human protease family member and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
PI US 2002115630 A1 20020822
AI US 2002-46643 A1 20020114 (10)
PRAI US 2001-262513P 20010118 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4105
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 56 OF 66 USPTFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:174981 USPTFULL
TI 18232, a novel dual specificity phosphatase and uses therefor
IN Meyers, Rachel A., Newton, MA, United States
Weich, Nadine, Brookline, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6420153 B1 20020716
AI US 2000-704139 20001101 (9)
PRAI US 2000-185772P 20000229 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Pak, Yong
LREP Fish & Richardson P.C.
CLMN Number of Claims: 15

ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 4450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 57 OF 66 USPTFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 7716 nucleic acid molecules, which encode novel ATPase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7716 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7716 gene has been introduced or disrupted. The invention still further provides isolated 7716 proteins, fusion proteins, antigenic peptides and anti-7716 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:157608 USPTFULL
TI 7716, a novel human ATPase and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002082212 A1 20020627
AI US 2001-908180 A1 20010718 (9)
PRAI US 2000-219740P 20000720 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 4113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 58 OF 66 USPTFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245 or 16228 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245 or 16228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245 or 16228 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245 or 16228 proteins, fusion proteins, antigenic peptides and anti-13237, -18480, -2245 or -16228 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:133840 USPTFULL
TI 13237, 18480, 2245 or 16228 novel human protein kinase molecules and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plains, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Tsai, Fong Ying, Newton, MA, UNITED STATES
PI US 2002068698 A1 20020606
AI US 2001-910150 A1 20010718 (9)
PRAI US 2000-219028P 20000718 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2382
CLMN Number of Claims: 23

ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 5427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 59 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 18221 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18221 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18221 gene has been introduced or disrupted. The invention still further provides isolated 18221 proteins, fusion proteins, antigenic peptides and anti-18221 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing hematopoietic disorders are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:126888 USPATFULL
TI 18221, a novel dual specificity phosphatase and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002065406 A1 20020530
AI US 2001-815419 A1 20010322 (9)
PRAI US 2000-191858P 20000324 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 5161

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 60 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 16658, 14223, and 16002 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16658, 14223, and 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16658, 14223, and 16002 gene has been introduced or disrupted. The invention still further provides isolated 16658, 14223, and 16002 proteins, fusion proteins, antigenic peptides and anti-16658, -14223, and -16002 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:119591 USPATFULL
TI 16658, 14223, and 16002, novel human kinases and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002061574 A1 20020523
AI US 2001-922138 A1 20010803 (9)
PRAI US 2000-229299P 20000901 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 4922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 61 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:119590 USPATFULL
TI 18431 and 32374, novel human protein kinase family members and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002061573 A1 20020523
AI US 2001-916790 A1 20010727 (9)
PRAI US 2000-221543P 20000728 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 4936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 62 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 26908 nucleic acid molecules, which encode novel G-protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26908 gene has been introduced or disrupted. The invention still further provides isolated 26908 proteins, fusion proteins, antigenic peptides and anti-26908 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:72625 USPATFULL
TI 26908 novel G protein-coupled receptors and uses therefor
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
PI US 2002039762 A1 20020404
AI US 2001-863200 A1 20010522 (9)
PRAI US 2000-206019P 20000522 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)
LN.CNT 4248
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 63 OF 66 USPATFULL on STN

AB The invention provides isolated nucleic acids molecules, designated 38692 or 21117 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38692 or 21117 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38692 or 21117 gene has been introduced or disrupted. The invention still further provides isolated 38692 or 21117 proteins, fusion proteins, antigenic peptides and anti-38692 or 21117 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:60972 USPATFULL
TI 38692 and 21117, novel dual specificity phosphatase molecules and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002034807 A1 20020321
US 6664089 B2 20031216
AI US 2001-816494 A1 20010323 (9)
PRAI US 2000-191858P 20000324 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 5760
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 64 OF 66 USPATFULL on STN

AB This invention relates to the identification, isolation, purification and manipulation of genetic stress response systems, and more particularly, to genes and expression products of those genes that are components of those systems. These components may be used to protect against potentially toxic stress factors. Stress factors include heat, alcohol and heavy metal ions. A family of stress protector proteins with apparent molecular weights about 100 kd, the hsp100 proteins, are an aspect of this invention. Other stress protector proteins are also within the scope of this invention to enhance or inhibit biological stress response. Applications of this invention to recombinant DNA technology, to commercial methods of food preparation and processing, and to methods of enhancing the stress response of plants and animals, are presented.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:131561 USPATFULL
TI Methods and compositions of genetic stress response systems
IN Lindquist, Susan, Chicago, IL, United States
PA Arch Development Corporation, Chicago, IL, United States (U.S. corporation)
PI US 5827685 19981027
AI US 1994-249380 19940525 (8)
RLI Continuation of Ser. No. US 1991-710187, filed on 3 Jun 1991, now abandoned
DT Utility
FS Granted

EXNAM Primary Examiner: Prouty, Rebecca E.
CLMN Number of Claims: 33
ECL Exemplary Claim: 27
DRWN 64 Drawing Figure(s); 27 Drawing Page(s)
LN.CNT 3269
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 65 OF 66 USPAT2 on STN

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:12981 USPAT2

TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

IN Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004157221 A9 20040812

AI US 2003-377072 A1 20030227 (10)

RLI Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, GRANTED, Pat. No. US 6686185 Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, GRANTED, Pat. No. US 6664089 Continuation of Ser. No. US 2001-815419, filed on 22 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

PRAI US 2000-215370P 20000629 (60)
US 2000-187455P 20000307 (60)
US 2000-199801P 20000426 (60)
US 2000-205508P 20000519 (60)
US 2000-191858P 20000324 (60)
US 2000-213688P 20000623 (60)
US 2000-218675P 20000717 (60)
US 2000-250932P 20001130 (60)
US 2000-226504P 20000821 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 66 OF 66 USPAT2 on STN

AB The invention provides isolated nucleic acids molecules, designated 38692 or 21117 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38692 or 21117 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38692 or 21117 gene has been introduced or disrupted. The invention still further provides isolated 38692 or 21117 proteins, fusion proteins, antigenic peptides and anti-38692 or 21117 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:60972 USPAT2
TI 38692 and 21117, novel dual specificity phosphatase molecules and uses therefor
IN Meyers, Rachel A., Newton, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6664089 B2 20031216
AI US 2001-816494 20010323 (9)
PRAI US 2000-191858P 20000324 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Pak, Yong
LREP Millennium Pharmaceuticals, Inc.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 5542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

5,597,457
6,267,935

422/245,1, 253
117/901


Eddie E. Scott 424-6897
Tel# (925) 422-7270
Fax# (925) 423-2231

10/218,764

Examiner's Notes

Elected claims 24-35 w/o traverse as of Nov 30, 2004

s (macro molecule?) (6a) (crystal?)
s (sample (4a) prepar?)
s (prescreen?) (8a) (protein# or concentration (4a) protein#)
s (assess? or evaluat? or test?)
s (multip? or plural?) (8a) (reagent#)
s (multip? or plural?) (8a) (sample# or sample (w) plate#)
s (incubate?)
s (ammonium (w) sulfate)
s (isopropanol)



11272 Rej

Claim 24, line 2, "protein concentration..."

Allowable Subject Matter { (Obj)

Claims 26-35

1) [S 1-23 are]

8.08 2) [A Kit for prescreening protein concentration for crystallization]

3) [400]

App 4) [245,100]

5) [S 24-35 are]

6) [Antg of sample preparation for prescreening protein concentration]

Mtd 7) []

8) []